As the sponsor of the Keynote Oncology Clinical Trials, Merck is passionate about improving health. We are committed to accelerating every step in the journey in our quest to bring treatment options to people with cancer.
Pembrolizumab is an investigational immunotherapy that may help the body’s immune system attack cancer cells. When a cancer cell binds to an immune cell, the immune cell can’t do its job. These trials want to see if pembrolizumab can block cancer cells from binding with immune cells to help allow the immune cells to work properly.
Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.
You can also call our clinical trial information center at 1-888-577-8839 to learn more.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab||590||Esophageal Neoplasms||Phase 3||Recruiting|
|Study of Pembrolizumab Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy||181||
|Study of Pembrolizumab in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction||180||
||Phase 2||Active, not recruiting|
There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.